Gilead Sciences

This study tested a single daily pill containing four HIV medicines in 129 teens and children with HIV. The goal was to see how the drug moves through the body, check safety, and confirm the right dose. Participants were either new to treatment or already had the virus under cont…

This study looked at 33 adults with well-controlled HIV who switched from a monthly injectable treatment (CAB+RPV) to a daily oral pill (B/F/TAF). The main goal was to check for serious side effects over 12 weeks. Researchers found that the switch was safe, with no major drug-rel…

This study checked the long-term safety of the drug sacituzumab govitecan in 25 people with metastatic solid tumors (cancer that has spread) who were already benefiting from the treatment. Researchers tracked side effects and lab test changes. The goal was to understand how safe …

This study tested whether two drugs—semaglutide and a combination of cilofexor and firsocostat—could reduce liver scarring in people with advanced liver disease (cirrhosis) caused by NASH. About 457 participants took one or both drugs or a placebo for 72 weeks. The goal was to se…

This early-stage study tested a new experimental drug, GS-3242, in 27 people living with HIV-1. The goal was to see if the drug is safe and can lower the amount of virus in the blood. Participants had not taken HIV medicines for at least 12 weeks before joining. The study measure…

This study tested the safety of two lab-made HIV antibodies (VRC07-523LS and CAP256V2LS) followed by an immune-boosting drug (vesatolimod) in 20 women with HIV who were already on standard antiretroviral therapy (ART). The goal was to see if this combination could help control th…

This study tested two experimental vaccines, GS-2829 and GS-6779, in 83 healthy volunteers and people with chronic hepatitis B. The main goal was to check safety and side effects, not to cure the disease. Researchers also looked at whether the vaccines boosted the body's immune r…

This study looked at how the drug bulevirtide (BLV) enters and leaves the bloodstream in people with normal and reduced liver function. Researchers measured drug levels and bile acids, and checked safety after multiple doses. The goal was to understand how liver impairment affect…

This study looked at how the body handles the drug seladelpar in 24 adults with primary biliary cholangitis (PBC) and varying degrees of liver impairment. Researchers measured drug levels in the blood and urine to see how liver function affects the drug's breakdown. The goal was …

This study looked at how the drug bulevirtide behaves in the body of people with chronic hepatitis D who have normal or reduced kidney function. Researchers measured drug levels in the blood and checked safety over several doses. The goal was to understand how kidneys affect the …